arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Liquidia Corp

LQDA
$67.51 ▼ -1.08 (-1.57%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
28 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Liquidia Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.0B
Dividend Yield —
Revenue Growth 1842.7% ↘
Op. Margin 49.8% ↗
ROIC 40.1% ↘
FCF / Share $0.78 ↗
Trailing P/E 80.4x
Price / Book 30.8x
FCF Yield 1.2%
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$171.68M
↑ +1842.7% —
Net Income Profit after all expenses
$52.86M
— 0.0% —
Operating Margin Operating profit as % of sales
49.8%
↑ +7.6% 7th
FCF / Share Free cash flow per share
$0.78
↑ +36.2% —
Long-Term Debt Long-term obligations
$19.88M
↑ +0.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
7
Returns ↓
4
Cash Quality ↓
43

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 28 quarters